Development of personalized combination cancer immunotherapy based on the patients’ immune status

Yutaka Kawakami, Li Qian, Naoshi Kawamura, Junichiro Miyazaki, Haruna Nagumo, Kinya Tsubota, Tomonari Kinoshita, Kenta Nakamua, Gaku Ohmura, Ryosuke Satomi, Juri Sugiyama, Hiroshi Nishio, Taeko Hayakawa, Boryana Popivanova, Sunthamala Nuchsupha, Tracy Hsin-Ju Liu, Hajime Kamijuku, Chie Kudo-Saito, Nobuo Tsukamoto, Toshiharu SakuraiTomonobu Fujita, Tomonori Yaguchi

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Citation (Scopus)

Abstract

Cancer immunotherapies, particularly immune-checkpoint blockade and T cell-based adoptive cell therapy, have recently been recognized as cancer treatments that show strong and durable responses even for advanced cancer patients with multiple metastases. The major issues in the development of cancer immunotherapy are the identification of biomarkers to distinguish responders and nonresponders, and the improvement of efficacy of immunotherapy possibly by combination with appropriate immune interventions targeting different key regulating points in the anti-tumor immune responses. Interestingly, pretreatment T cell immune status varies among cancer patients, and appears to correlate with responses to various cancer treatments including surgery, chemotherapy, radiation therapy, and immunotherapy. Balance of anti-tumor T cell induction pathway and immunosuppressive pathway, which are regulated by characteristics of both cancer cells and patients’ immune reactivity, may define the differential immune status among cancer patients along with environmental factors such as intestinal microbiota. The analysis of such mechanisms may lead to the identification of immune biomarkers and immune-modulating strategies for combination immunotherapies. Further research on human cancer immunopathology will lead to the development of effective personalized combination immunotherapies based on the evaluation of cancer patients’ immune status.

Original languageEnglish
Title of host publicationInflammation and Immunity in Cancer
PublisherSpringer Japan
Pages255-266
Number of pages12
ISBN (Print)9784431553274, 9784431553267
DOIs
Publication statusPublished - 2015 Jan 1

Fingerprint

Immunotherapy
Neoplasms
T-Lymphocytes
Biomarkers
Immunosuppressive Agents
Cell- and Tissue-Based Therapy
Radiotherapy
Neoplasm Metastasis
Drug Therapy

Keywords

  • Biomarkers
  • Cancer immunopathology
  • Cancer immunotherapy
  • Combination immunotherapy
  • Personalized therapy

ASJC Scopus subject areas

  • Medicine(all)
  • Immunology and Microbiology(all)

Cite this

Kawakami, Y., Qian, L., Kawamura, N., Miyazaki, J., Nagumo, H., Tsubota, K., ... Yaguchi, T. (2015). Development of personalized combination cancer immunotherapy based on the patients’ immune status. In Inflammation and Immunity in Cancer (pp. 255-266). Springer Japan. https://doi.org/10.1007/978-4-431-55327-4_20

Development of personalized combination cancer immunotherapy based on the patients’ immune status. / Kawakami, Yutaka; Qian, Li; Kawamura, Naoshi; Miyazaki, Junichiro; Nagumo, Haruna; Tsubota, Kinya; Kinoshita, Tomonari; Nakamua, Kenta; Ohmura, Gaku; Satomi, Ryosuke; Sugiyama, Juri; Nishio, Hiroshi; Hayakawa, Taeko; Popivanova, Boryana; Nuchsupha, Sunthamala; Hsin-Ju Liu, Tracy; Kamijuku, Hajime; Kudo-Saito, Chie; Tsukamoto, Nobuo; Sakurai, Toshiharu; Fujita, Tomonobu; Yaguchi, Tomonori.

Inflammation and Immunity in Cancer. Springer Japan, 2015. p. 255-266.

Research output: Chapter in Book/Report/Conference proceedingChapter

Kawakami, Y, Qian, L, Kawamura, N, Miyazaki, J, Nagumo, H, Tsubota, K, Kinoshita, T, Nakamua, K, Ohmura, G, Satomi, R, Sugiyama, J, Nishio, H, Hayakawa, T, Popivanova, B, Nuchsupha, S, Hsin-Ju Liu, T, Kamijuku, H, Kudo-Saito, C, Tsukamoto, N, Sakurai, T, Fujita, T & Yaguchi, T 2015, Development of personalized combination cancer immunotherapy based on the patients’ immune status. in Inflammation and Immunity in Cancer. Springer Japan, pp. 255-266. https://doi.org/10.1007/978-4-431-55327-4_20
Kawakami Y, Qian L, Kawamura N, Miyazaki J, Nagumo H, Tsubota K et al. Development of personalized combination cancer immunotherapy based on the patients’ immune status. In Inflammation and Immunity in Cancer. Springer Japan. 2015. p. 255-266 https://doi.org/10.1007/978-4-431-55327-4_20
Kawakami, Yutaka ; Qian, Li ; Kawamura, Naoshi ; Miyazaki, Junichiro ; Nagumo, Haruna ; Tsubota, Kinya ; Kinoshita, Tomonari ; Nakamua, Kenta ; Ohmura, Gaku ; Satomi, Ryosuke ; Sugiyama, Juri ; Nishio, Hiroshi ; Hayakawa, Taeko ; Popivanova, Boryana ; Nuchsupha, Sunthamala ; Hsin-Ju Liu, Tracy ; Kamijuku, Hajime ; Kudo-Saito, Chie ; Tsukamoto, Nobuo ; Sakurai, Toshiharu ; Fujita, Tomonobu ; Yaguchi, Tomonori. / Development of personalized combination cancer immunotherapy based on the patients’ immune status. Inflammation and Immunity in Cancer. Springer Japan, 2015. pp. 255-266
@inbook{54db0b4ded2e4dc0bf6a05c75e2ec26d,
title = "Development of personalized combination cancer immunotherapy based on the patients’ immune status",
abstract = "Cancer immunotherapies, particularly immune-checkpoint blockade and T cell-based adoptive cell therapy, have recently been recognized as cancer treatments that show strong and durable responses even for advanced cancer patients with multiple metastases. The major issues in the development of cancer immunotherapy are the identification of biomarkers to distinguish responders and nonresponders, and the improvement of efficacy of immunotherapy possibly by combination with appropriate immune interventions targeting different key regulating points in the anti-tumor immune responses. Interestingly, pretreatment T cell immune status varies among cancer patients, and appears to correlate with responses to various cancer treatments including surgery, chemotherapy, radiation therapy, and immunotherapy. Balance of anti-tumor T cell induction pathway and immunosuppressive pathway, which are regulated by characteristics of both cancer cells and patients’ immune reactivity, may define the differential immune status among cancer patients along with environmental factors such as intestinal microbiota. The analysis of such mechanisms may lead to the identification of immune biomarkers and immune-modulating strategies for combination immunotherapies. Further research on human cancer immunopathology will lead to the development of effective personalized combination immunotherapies based on the evaluation of cancer patients’ immune status.",
keywords = "Biomarkers, Cancer immunopathology, Cancer immunotherapy, Combination immunotherapy, Personalized therapy",
author = "Yutaka Kawakami and Li Qian and Naoshi Kawamura and Junichiro Miyazaki and Haruna Nagumo and Kinya Tsubota and Tomonari Kinoshita and Kenta Nakamua and Gaku Ohmura and Ryosuke Satomi and Juri Sugiyama and Hiroshi Nishio and Taeko Hayakawa and Boryana Popivanova and Sunthamala Nuchsupha and {Hsin-Ju Liu}, Tracy and Hajime Kamijuku and Chie Kudo-Saito and Nobuo Tsukamoto and Toshiharu Sakurai and Tomonobu Fujita and Tomonori Yaguchi",
year = "2015",
month = "1",
day = "1",
doi = "10.1007/978-4-431-55327-4_20",
language = "English",
isbn = "9784431553274",
pages = "255--266",
booktitle = "Inflammation and Immunity in Cancer",
publisher = "Springer Japan",

}

TY - CHAP

T1 - Development of personalized combination cancer immunotherapy based on the patients’ immune status

AU - Kawakami, Yutaka

AU - Qian, Li

AU - Kawamura, Naoshi

AU - Miyazaki, Junichiro

AU - Nagumo, Haruna

AU - Tsubota, Kinya

AU - Kinoshita, Tomonari

AU - Nakamua, Kenta

AU - Ohmura, Gaku

AU - Satomi, Ryosuke

AU - Sugiyama, Juri

AU - Nishio, Hiroshi

AU - Hayakawa, Taeko

AU - Popivanova, Boryana

AU - Nuchsupha, Sunthamala

AU - Hsin-Ju Liu, Tracy

AU - Kamijuku, Hajime

AU - Kudo-Saito, Chie

AU - Tsukamoto, Nobuo

AU - Sakurai, Toshiharu

AU - Fujita, Tomonobu

AU - Yaguchi, Tomonori

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Cancer immunotherapies, particularly immune-checkpoint blockade and T cell-based adoptive cell therapy, have recently been recognized as cancer treatments that show strong and durable responses even for advanced cancer patients with multiple metastases. The major issues in the development of cancer immunotherapy are the identification of biomarkers to distinguish responders and nonresponders, and the improvement of efficacy of immunotherapy possibly by combination with appropriate immune interventions targeting different key regulating points in the anti-tumor immune responses. Interestingly, pretreatment T cell immune status varies among cancer patients, and appears to correlate with responses to various cancer treatments including surgery, chemotherapy, radiation therapy, and immunotherapy. Balance of anti-tumor T cell induction pathway and immunosuppressive pathway, which are regulated by characteristics of both cancer cells and patients’ immune reactivity, may define the differential immune status among cancer patients along with environmental factors such as intestinal microbiota. The analysis of such mechanisms may lead to the identification of immune biomarkers and immune-modulating strategies for combination immunotherapies. Further research on human cancer immunopathology will lead to the development of effective personalized combination immunotherapies based on the evaluation of cancer patients’ immune status.

AB - Cancer immunotherapies, particularly immune-checkpoint blockade and T cell-based adoptive cell therapy, have recently been recognized as cancer treatments that show strong and durable responses even for advanced cancer patients with multiple metastases. The major issues in the development of cancer immunotherapy are the identification of biomarkers to distinguish responders and nonresponders, and the improvement of efficacy of immunotherapy possibly by combination with appropriate immune interventions targeting different key regulating points in the anti-tumor immune responses. Interestingly, pretreatment T cell immune status varies among cancer patients, and appears to correlate with responses to various cancer treatments including surgery, chemotherapy, radiation therapy, and immunotherapy. Balance of anti-tumor T cell induction pathway and immunosuppressive pathway, which are regulated by characteristics of both cancer cells and patients’ immune reactivity, may define the differential immune status among cancer patients along with environmental factors such as intestinal microbiota. The analysis of such mechanisms may lead to the identification of immune biomarkers and immune-modulating strategies for combination immunotherapies. Further research on human cancer immunopathology will lead to the development of effective personalized combination immunotherapies based on the evaluation of cancer patients’ immune status.

KW - Biomarkers

KW - Cancer immunopathology

KW - Cancer immunotherapy

KW - Combination immunotherapy

KW - Personalized therapy

UR - http://www.scopus.com/inward/record.url?scp=84943385960&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84943385960&partnerID=8YFLogxK

U2 - 10.1007/978-4-431-55327-4_20

DO - 10.1007/978-4-431-55327-4_20

M3 - Chapter

AN - SCOPUS:84943385960

SN - 9784431553274

SN - 9784431553267

SP - 255

EP - 266

BT - Inflammation and Immunity in Cancer

PB - Springer Japan

ER -